<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335518">
  <stage>Registered</stage>
  <submitdate>10/09/2010</submitdate>
  <approvaldate>15/09/2010</approvaldate>
  <actrnumber>ACTRN12610000768099</actrnumber>
  <trial_identification>
    <studytitle>Ginseng extract for patients with moderate Chronic Obstructive Pulmonary Disease (COPD)</studytitle>
    <scientifictitle>The effect of a standardised ginseng extract on the quality of life and respiratory symptoms of patients with moderate chronic obstructive pulmonary disease: a multi-centre, randomised, double-blind, placebo controlled trial</scientifictitle>
    <utrn />
    <trialacronym>Ginseng Extract And Respiratory Symptoms (GEARS)</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Obstructive Pulmonary Disease (COPD)</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Chronic obstructive pulmonary disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Alternative and complementary medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Oral Ginseng extract capsules. 100mg/twice a day for a total of 24 weeks.</interventions>
    <comparator>Oral placebo capsules. 100mg/twice a day for a total of 24 weeks.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>St Georges Respiratory Questionnaire (SGRQ)</outcome>
      <timepoint>6 times; baseline (week 0), week 4, week 16, week 28, week 40, week 52</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Short Form Quality of Life Questionnaire (SF-36)</outcome>
      <timepoint>6 times; baseline (week 0), week 4, week 16, week 28, week 40, week 52</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>COPD Assessment Test (CAT)</outcome>
      <timepoint>6 times; baseline (week 0), week 4, week 16, week 28, week 40, week 52</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Spirometry: Forced Expiratory Volume in 1 second (FEV1) and Forced Vital Capacity (FVC)</outcome>
      <timepoint>6 times; baseline (week 0), week 4, week 16, week 28, week 40, week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood biochemistry for liver and kidney functions and full blood examination</outcome>
      <timepoint>2 times; baseline (week 0) and week 28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse Events: any undesirable symptom or sign including abnormal laboratory results will be recorded, noting type of event, duration and intensity.</outcome>
      <timepoint>Reported throughout the trial (52 weeks) duration</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency, nature and severity of exacerbations, recorded by clinical assesments.</outcome>
      <timepoint>5 times; week 4, week 16, week 28, week 40, week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Relief Medication Usage (Ventolin) recorded in patient diaries.</outcome>
      <timepoint>5 times; week 4, week 16, week 28, week 40, week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Medical Resource Utilisation reported through patient and local physician inquiry.</outcome>
      <timepoint>5 times; week 4, week 16, week 28, week 40, week 52</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Both male and female, aged 40 to 80 (inclusive);
2. Ex-smokers (ceased smoking at least three months before randomisation) and agree to refrain from smoking throughout the trial;
3. Satisfy the COPD diagnostic criteria for moderate (stage II) defined by the Global initiative for chronic Obstructive Lung Disease (GOLD),
FEV1/ FVC ratio &lt; 0.7 (post-bronchodilator value) and, FEV1 between 50% and 80%;
4. Are clinically stable, that is, did not experience an acute infective exacerbation of COPD from at least 4 weeks prior to trial entry;
5. Meet the Chinese Medicine diagnostic criteria for Lung Qi deficiency or Lung &amp; Spleen Qi deficiency;
6. Informed written consent for participation in the study.</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Current smokers; 2. Those who have been diagnosed as alpha1-antitrypsin deficient; 3. A reduction in FEV1 &gt; 12% and 200mls or a 4 point or more worsening of their SGRQ compared to baseline or FEV1 &lt; 50% at visit 2 (week 4); 4. Those with a history of current asthma or a history of chronic systemic infections or inflammatory conditions in the last 3 months; 5. Pregnancy, breast-feeding or women intending to become pregnant during the course of the study; 6. Those with serious illnesses, which make them unsuitable for the study, e.g., severe heart, liver and kidney diseases; 7. Individuals unable to adequately perform spirometry tests; 8. Those who are taking long-term immunosuppressive agents or immuno-stimulants; 9. Individuals with an allergic history to ginseng products; 10. Those currently using a ginseng-containing product or have used a ginseng product within the last three months; 11. Those who are current users of monoamine oxidase inhibitor antidepressants, anticoagulants and antihyperglycaemic medications; 12. Individuals having pulmonary rehabilitation within three months of the commencement of the study, or intend to enter pulmonary rehabilitation during the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Treatment allocation will be entered into sequentially numbered, opaque sealed envelopes. Eligible subjects will draw an envelope before commencement of treatment.</concealment>
    <sequence>All eligible subjects will be randomised using block randomisation sequences generated by a computer and stratified by site.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>15/09/2010</anticipatedstartdate>
    <actualstartdate>13/12/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/07/2016</actualenddate>
    <samplesize>168</samplesize>
    <actualsamplesize>168</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/07/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <postcode>3084</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Royal Melbourne Institute of Technology (RMIT) University</primarysponsorname>
    <primarysponsoraddress>PO Box 71, Bundoora
VIC, 3083</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC)</fundingname>
      <fundingaddress>16 Marcus Clarke Street,
Canberra, ACT, 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>National Institute of Complementary Medicine (NICM)</fundingname>
      <fundingaddress>Locked Bag 1797
SOUTH PENRITH DC NSW 1797</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Austin Health</sponsorname>
      <sponsoraddress>145 Studley Road 
PO Box 5555
Heidelberg
Victoria
Australia 3084</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Eastern Health</sponsorname>
      <sponsoraddress>5 Arnold Street
Box Hill 
VIC 3128</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will investigate the safety profile and efficacy of a standardised extract of Panax ginseng with a focus on quality of life improvements in adults with moderate chronic obstructive pulmonary disease. The study is a multi-centre, randomised, double-blind, placebo-controlled clinical trial. The study will consist of three phases: a run in period of 4 weeks, 24 weeks of treatment and 24 weeks of follow-up.</summary>
    <trialwebsite>www.rmit.edu.au/chinese-med</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Austin Health Human Research Ethics Committee (HREC)</ethicname>
      <ethicaddress>Research ethics unit,
Henry Buck Building,
Austin Hospital,
145 Studley Road,
PO Box 5555, Heidelberg,
Victoria, Australia 3084</ethicaddress>
      <ethicapprovaldate>10/05/2010</ethicapprovaldate>
      <hrec>HREC/10/Austin/8</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Eastern Health Research &amp; Ethics Committee</ethicname>
      <ethicaddress>PO Box 94
Box Hill South
VIC 3128</ethicaddress>
      <ethicapprovaldate>12/08/2010</ethicapprovaldate>
      <hrec>E90/0910</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>RMIT Human Research Ethics Committee (HREC)</ethicname>
      <ethicaddress>GPO Box 2476V
Melbourne VIC 3001</ethicaddress>
      <ethicapprovaldate>11/06/2010</ethicapprovaldate>
      <hrec>E31/10</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Charlie Xue</name>
      <address>World Health Organization (WHO)  Collaborating Centre for Traditional Medicine
RMIT University
PO BOX 71
Bundoora 
VIC 3083</address>
      <phone>+61 3 9925 7745</phone>
      <fax>+61 3 9925 7178</fax>
      <email>gears@rmit.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Charlie Xue</name>
      <address>World Health Organization (WHO) Collaborating Centre for Traditional Medicine
RMIT University
PO BOX 71
Bundoora 
VIC 3083</address>
      <phone>+61 3 9925 7745</phone>
      <fax>+61 3 9925 7178</fax>
      <email>gears@rmit.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Johannah Shergis</name>
      <address>World Health Organization (WHO)  Collaborating Centre for Traditional Medicine
RMIT University
PO BOX 71
Bundoora 
VIC 3083</address>
      <phone>+61 3 9925 7746</phone>
      <fax>+61 3 9925 7178</fax>
      <email>gears@rmit.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Charlie Xue</name>
      <address>RMIT University
PO BOX 71
Bundoora
VIC 3073</address>
      <phone>+61399257360</phone>
      <fax />
      <email>charlie.xue@rmit.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>